Journal article
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial
Abstract
Given the early use of triplet and quadruplet regimens, most patients with multiple myeloma (MM) will be exposed and/or refractory to PIs, IMiDs, and anti-CD38 mAbs after first- or second-line treatment. Effective treatment for this group of triple class exposed/refractory (TCE/R) patients is crucial. Here we present a post-hoc subgroup analysis of TCE/R patients treated on the ALGONQUIN study of belantamab mafodotin plus …
Authors
McCurdy A; Reece D; Louzada ML; White D; Parkin S; Chu MP; Kotb R; Mian H; Othman I; Su J
Journal
Blood Cancer Journal, Vol. 14, No. 1,
Publisher
Springer Nature
DOI
10.1038/s41408-024-01135-2
ISSN
2044-5385